title: Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring.
abstract: Circulating tumor DNA in plasma and serum has been demonstrated to reflect the biological characteristics of tumors, including the rates of apoptosis and necrosis. Aberrant promoter methylation has increasingly emerged as a fundamental molecular abnormality associated with loss of critical gene functions during carcinogenesis. This epigenetic inheritance has significant biological implications for early tumor initiation and cancer progression or metastasis formation. The promoter-region methylation is crucial in transcriptional silencing of tumor suppressor genes, DNA repair genes, and metastasis inhibitor genes, and is linked to the predisposition of genetic alterations of other cancer-associated genes. Of clinical relevance, epigenetic markers in plasma and serum have recently been established as specific and sensitive biomarkers for early and noninvasive screening, risk assessment, and monitoring of neoplastic diseases. A panel of epigenetic markers may possibly allow the detection of circulating tumor DNA in virtually all patients with different cancer types. Furthermore, the prognostic value of aberrant DNA methylation and therapeutic implications of demethylation of methylated genes could further improve the management of patients with different kinds of cancer.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China. ihnwong@hkucc.hku.hk
authors.forename: I H
authors.initials: IH
authors.lastname: Wong
authors.forename: Y M
authors.initials: YM
authors.lastname: Lo
authors.forename: P J
authors.initials: PJ
authors.lastname: Johnson
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D019175:DNA Methylation; D020868:Gene Silencing; D006801:Humans; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D014158:Transcription, Genetic; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D000509:alpha-Fetoproteins